Lipid abnormalities in patients with chronic kidney disease

Contributions to Nephrology

Volumn 171, Issue , 2011, Pages 135-142

  Keane, William F ^a,c   Tomassini, Joanne E ^b   Neff, David R ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LIPID; LIPOPROTEIN; LIPOPROTEIN A; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DYSLIPIDEMIA; HUMAN; KIDNEY DISEASE; METABOLISM;

APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; KIDNEY DISEASES; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; TRIGLYCERIDES;

EID: 79958180045     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000327317     Document Type: Article

References (30)

1. McCullough PA: Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004;13:591-600. (Pubitemid 39506906)
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52: 1527-1539.
3. National Kidney Foundation: K/ DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003;41(Suppl 3):S1-S92.
4. Kaysen GA: Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutrit 2009;19:73-77.
5. Vaziri ND, Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011;31:189-196.
6. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290: F262-F272. (Pubitemid 43724980)
7. Lacquaniti A, Bolignano D, Donato V, Bono C, Razio MR, Buemi M: Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010;33:100-110.
8. Kruit JK, Groen AK, van Berkel TJ, Kuipers F: Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 2006;12:6429-6439. (Pubitemid 44742578)
9. Redgrave TG: Chylomicron metabolism. Biochem Soc Trans 2004;32: 79-82. (Pubitemid 38283018)
10. Turley SD, Dietschy JM: Sterol absorption by the small intestine. Curr Opin Lipidol 2003;14:233-240. (Pubitemid 36688201)
11. Vaziri ND, Liang KH: Downregulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996;50: 1928-1935. (Pubitemid 26417536)
12. Kim C, Vaziri ND: Down- regulation of hepatic LDL receptor- related protein (LRP) in chronic renal failure. Kidney Int 2005;67:1028-1032. (Pubitemid 41623326)
13. Liang KH, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998; 53:626-630. (Pubitemid 28124276)
14. Vaziri ND, Liang KH: Downregulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 1997;51:913-919. (Pubitemid 27157982)
15. Vaziri ND, Liang KH: Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996;50:887-893. (Pubitemid 26302677)
16. Sato T, Liang KH, Vaziri ND: Protein restriction and AST- 120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int 2003;64:1780-1786. (Pubitemid 37323707)
17. Klin M, Smogorzewski M, Ni ZM, Zhang GX, Massry SG: Abnormalities in hepatic lipase in chronic renal failure - role of excess parathyroid hormone. J Clin Invest 1996;97:2167-2173.
18. Liang K, Vaziri ND: Down- regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 1997;51:1933-1937. (Pubitemid 27252765)
19. Deighan CJ, Caslake MJ, McConnell M, Boulton- Jones JM, Packard CJ: The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis 2001;157: 211-220. (Pubitemid 32539373)
20. St- Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, Lamarche B: Low- density lipoprotein subfractions and the long- term risk of ischemic heart disease in men: 13- year follow- up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553-559. (Pubitemid 40315677)
21. Kaysen GA: New insights into lipid metabolism in chronic kidney disease: what are the practical implications? Blood Purif 2009;27:86-91.
22. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11:105-115. (Pubitemid 30020432)
23. Kuboyama M, Ageta M, Ishihara T, Fujiura Y, Kashio N, Ikushima I: Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb 2003;10: 283-289.
24. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta- analysis of prospective studies. Circulation 2000; 102: 1082-1085.
25. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR- B1 and Apo A- I expression in chronic renal failure. Nephrol Dial Transplant 1999;14: 1462-1466. (Pubitemid 29241738)
26. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflammatory properties of high- density lipoprotein distinguish patients from control subjects better than high- density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108: 2751-2756. (Pubitemid 37498976)
27. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high- density lipoprotein in chronic kidney disease. Transl Res 2009;153:77-85.
28. Zhao Y, Marcel YL: Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 1996;35: 7174-7180. (Pubitemid 26182109)
29. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R: Ectopic beta- chain of ATP synthase is an apolipoprotein A- I receptor in hepatic HDL endocytosis. Nature 2003;421:75-79. (Pubitemid 36077087)
30. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab 2006;2:504-511. (Pubitemid 44353291)